ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 2743

CD27 Is a Key Regulator of T Cell Responses

Michael Scully1, Nicole Wunderler2, Holger Babbe1, Yevgeniya Orlovsky2, Galina Obmolova3, Ann Cai1, Heath Guay4, Jacqueline Benson4 and Tatiana Ort1, 1Research Immunology, Immunology Research, Janssen Research and Development, LLC, Spring House, PA, 2Immunology Research, Janssen Research and Development, LLC, Spring House, PA, 3Biologics Research, Janssen Research and Development, LLC, Spring House, PA, 4Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: Immune regulation, T cells and co-stimulation

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity

Session Type: Abstract Submissions (ACR)

Background/Purpose: CD27 is a member of the TNF superfamily of receptors that is expressed on a majority of natural killer (NK) cells, T cells, memory B cells and antibody-secreting plasma cells in humans.  CD70 is the only known ligand for CD27 and is transiently expressed on activated dendritic cells, B cells and T cells.  Much of our understanding of the immunological role of CD27 comes from studies with mouse models, which suggest that CD27 is a key regulator of NK cell, T cell and B cell responses. Here, we used an in-house generated neutralizing, antagonistic antibody to evaluate the role of CD27 in regulating human and primate immune responses using in vitro and in vivo models.

Methods: To examine the role of CD27 in immune cell biology, we generated a neutralizing, antagonistic and non-depleting human anti-human CD27 antibody.  To assess the contribution of CD27 signaling to human immune responses in vitro, we examined the effects of CD27 blockade on Ig-production by B cells, proliferation of naive CD4+ T cells and cytokine production by healthy volunteer PBMCs in vitro.  To understand the role of CD27 on immune responses in vivo, we examined the effects of CD27 blockade on T and B cell responses in a cynomolgus monkey Delayed Type Hypersensitivity (DTH) model.  To further explore the contribution of CD27 to human T cell responses in vivo, we examined the effects of CD27 blockade on human T cell engraftment in the NSG (NOD/SCID IL-2Rγ-/-) human CD45+ peripheral blood cell → mouse GVH model.  

Results: We found that neutralizing the CD27 pathway inhibited CD70-induced Ig-secretion by activated human B cells, whereas blockade of CD27 in an autologous T cell:B cell co-culture model did not impact Ig-secretion in vitro (despite expression of CD70 on cells in this system).  Treatment with an anti-CD27 antibody dose-dependently attenuated CD70-mediated induced proliferation of primary human CD4+ T cells and decreased the production of pro-inflammatory cytokines by healthy control PBMCs in vitro.  Treatment with an anti-CD27 antibody reduced human CD45+ CD4+ and CD8+ cell numbers in the spleen and peripheral blood of host mice in the human cell → NSG mouse GVH model.  Blockade of CD27 reduced T cell infiltration into the challenge site in response to a neo-antigen, but did not impact antigen-specific antibody titers in a cynomolgus monkey DTH model.

Conclusion: These data demonstrate that CD27 can promote Ig-production by human B cells, but may play a redundant role in some types of B cell responses.  In contrast, CD27 appears to play a critical role in the generation of both CD4+ and CD8+ T cell responses.  These data suggest that the CD27 pathway modulates the activity of multiple human immune cell types, and that blockade of the CD27 pathway may present a novel therapeutic strategy for the treatment of immune mediated diseases.


Disclosure:

M. Scully,

Janssen Research and Development,

3;

N. Wunderler,

Janssen Research and Development,

3;

H. Babbe,

Janssen Research and Development,

3;

Y. Orlovsky,

Janssen Research and Development,

3;

G. Obmolova,

Janssen Research and Development,

3;

A. Cai,

Janssen Research and Development,

3;

H. Guay,

Janssen Research and Development,

3;

J. Benson,

Janssen Research and Development, LLC.,

3;

T. Ort,

Janssen Research and Development,

3.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2014

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd27-is-a-key-regulator-of-t-cell-responses/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology